Prana gets OK for Alzheimer's drug trial

11/23/2011 | Wall Street Journal, The · MarketWatch

Prana Biotechnology said it got the OK from Australia's Austin Health Research Ethics Committee to move forward with a long-term Phase II trial of PBT2, its experimental drug for mild Alzheimer's disease. Researchers will use PiB-PET imaging to measure the drug's effect on amyloid deposits in patients' brains and F-FDG PET to determine effects on increasing brain activity.

View Full Article in:

Wall Street Journal, The · MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA